LLY Stock Analysis: Eli Lilly | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 1.078.115m USD | 12M Return: 70.1% | US5324571083 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.99B
EPS Trend: 99.6%
Qual. Beats: 2
Rev. Trend: 99.5%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company headquartered in Indianapolis, Indiana, that discovers, develops, manufactures, and markets human pharmaceutical products across the United States, Europe, China, Japan, and other international markets. Founded in 1876, the company operates one of the most diversified product portfolios in the pharmaceutical industry, spanning cardiometabolic health, oncology, immunology, and neuroscience therapeutic areas.
The companys cardiometabolic franchise includes insulin products (Humalog, Humulin, Basaglar), type 2 diabetes therapies (Jardiance, Mounjaro, Trulicity), and the obesity treatment Zepbound. Its oncology offerings include Verzenio for breast cancer, Cyramza for gastric cancer, and Erbitux for colorectal and head and neck cancers. Immunology products cover Ebglyss, Olumiant, Omvoh, and Taltz, while its neuroscience portfolio includes Emgality for migraine and Kisunla for Alzheimers disease. Notably, Mounjaro and Zepbound are part of the GLP-1 receptor agonist class, a category that has reshaped treatment standards for type 2 diabetes and obesity and become a major focus of industry growth and competition.
Eli Lilly pursues its pipeline through a combination of internal R&D and external partnerships, including collaborations with Boehringer Ingelheim on the Jardiance family, Roche/Genentech on lebrikizumab, license agreements with Almirall and Chugai Pharmaceutical, and a strategic collaboration with Ascidian Therapeutics on monogenic kidney diseases. As a Mega Cap pharmaceutical company, Lillys business model relies on patent-protected branded biologics and small molecules, high R&D investment, and global commercialization to sustain revenue across multiple therapeutic categories.
- Zepbound obesity drug sales outpace expectations
- Mounjaro supply expansion lifts GLP-1 revenue
- Orforglipron oral GLP-1 phase 3 data due
| Net Income: 26.7b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 14.14 > 1.0 |
| NWC/Revenue: 21.25% < 20% (prev 20.34%; Δ 0.91% < -1%) |
| CFO/TA 0.20 > 3% & CFO 28.1b > Net Income 26.7b |
| Net Debt (46.4b) to EBITDA (37.1b): 1.25 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (893.7m) vs 12m ago -0.68% < -2% |
| Gross Margin: 84.01% > 18% (prev 82.64%; Δ 1.37% > 0.5%) |
| Asset Turnover: 65.51% > 50% (prev 52.77%; Δ 12.74% > 0%) |
| Interest Coverage Ratio: 35.72 > 6 (EBIT TTM 35.0b / Interest Expense TTM 979.6m) |
| A: 0.12 (Total Current Assets 64.7b - Total Current Liabilities 47.7b) / Total Assets 142b |
| B: 0.22 (Retained Earnings 31.9b / Total Assets 142b) |
| C: 0.29 (EBIT TTM 35.0b / Avg Total Assets 122b) |
| D: 0.31 (Book Value of Equity 33.9b / Total Liabilities 108b) |
| Altman-Z'' = 3.77 = AA |
| DSRI: 0.91 (Receivables 23.5b/17.2b, Revenue 79.7b/53.3b) |
| GMI: 0.98 (GM 82.64% / 84.01%) |
| AQI: 1.12 (AQ_t 0.34 / AQ_t-1 0.30) |
| SGI: 1.50 (Revenue 79.7b / 53.3b) |
| TATA: -0.01 (NI 26.7b - CFO 28.1b) / TA 142b) |
| Beneish M = -2.69 (Cap -4..+1) = A |
As of August 17, 2026, the stock is trading at USD 1180.16 with a total of 2,115,056 shares traded. Over the past week, the price has changed by -0.33%, over one month by +1.08%, over three months by +19.61% and over the past year by +70.13%.
Current recommended Stop Loss: 1129.50 (which is 4.3% or 1.2 ATR below the current price).
Eli Lilly has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy LLY.
- StrongBuy: 18
- Buy: 6
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 1299 | 10.1% |
P/E Trailing = 40.9831
P/E Forward = 33.8983
P/S = 13.5329
P/B = 32.4124
P/EG = 1.5497
Revenue TTM = 79.7b USD
EBIT TTM = 35.0b USD
EBITDA TTM = 37.1b USD
Long Term Debt = 47.9b USD (from longTermDebt, last quarter)
Short Term Debt = 7.05b USD (from shortTermDebt, last quarter)
Debt = 55.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 486.7m
Net Debt = 46.4b USD (calculated: Debt 55.4b - CCE 8.95b)
Enterprise Value = 1125b USD (1078b + Debt 55.4b - CCE 8.95b)
Interest Coverage Ratio = 35.72 (Ebit TTM 35.0b / Interest Expense TTM 979.6m)
EV/FCF = 56.08x (Enterprise Value 1125b / FCF TTM 20.1b)
FCF Yield = 1.78% (FCF TTM 20.1b / Enterprise Value 1125b)
FCF Margin = 25.17% (FCF TTM 20.1b / Revenue TTM 79.7b)
Net Margin = 33.53% (Net Income TTM 26.7b / Revenue TTM 79.7b)
Gross Margin = 84.01% ((Revenue TTM 79.7b - Cost of Revenue TTM 12.7b) / Revenue TTM)
Gross Margin QoQ = 85.78% (prev 81.93%)
Tobins Q-Ratio = 7.90 (Enterprise Value 1125b / Total Assets 142b)
Interest Expense / Debt = 1.77% (Interest Expense 979.6m / Debt 55.4b)
Taxrate = 20.49% (6.88b / 33.6b)
NOPAT = 27.8b (EBIT 35.0b * (1 - 20.49%))
Current Ratio = 1.35 (Total Current Assets 64.7b / Total Current Liabilities 47.7b)
Debt / Equity = 1.64 (Debt 55.4b / totalStockholderEquity, last quarter 33.9b)
Debt / EBITDA = 1.25 (Net Debt 46.4b / EBITDA 37.1b)
Debt / FCF = 2.32 (Net Debt 46.4b / FCF TTM 20.1b)
Total Stockholder Equity = 28.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.96% (Net Income 26.7b / Total Assets 142b)
RoE = 92.58% (Net Income TTM 26.7b / Total Stockholder Equity 28.9b)
RoCE = 45.61% (EBIT 35.0b / Capital Employed (Equity 28.9b + L.T.Debt 47.9b))
RoIC = 28.50% (NOPAT 27.8b / Invested Capital 97.6b)
WACC = 6.62% (E(1078b)/V(1134b) * Re(6.89%) + D(55.4b)/V(1134b) * Rd(1.77%) * (1-Tc(0.20)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.08 | Cagr: -0.50%
[DCF] Terminal Value 75.44% ; FCFF base≈20.1b ; Y1≈20.1b ; Y5≈21.3b
[DCF] Fair Price = 320.0 (EV 332b - Net Debt 46.4b = Equity 285b / Shares 891.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 99.59 | EPS CAGR: 91.62% | SUE: 3.39 | # QB: 2
Revenue Correlation: 99.51 | Revenue CAGR: 39.73% | SUE: 2.46 | # QB: 5
EPS current Quarter (2026-09-30): EPS=9.78 | Chg30d=+3.47% | Revisions=+0% | Analysts=17
EPS current Year (2026-12-31): EPS=36.42 | Chg30d=+1.27% | Revisions=-86% | GrowthEPS=+50.4% | GrowthRev=+34.2%
EPS next Year (2027-12-31): EPS=46.56 | Chg30d=+3.88% | Revisions=+38% | GrowthEPS=+27.8% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: -21% (up=19, down=30)